Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 12/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.44 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11317727 | 0.83 | MAPT (0.48) | DPP8DPP9DPP7NAMPTHRH3 | |
| SCHEMBL20612064 | 0.83 | DPP8 (0.54) | DPP8DPP9DPP7NAMPTTAS1R3 | |
| SCHEMBL12942525 | 0.82 | NAMPT (0.52) | DPP8DPP9DPP7NAMPTTAS1R3 | |
| SCHEMBL17169484 | 0.82 | NOTUM (0.55) | NAMPTTAS1R3TAS1R1TAS1R2HRH3 | |
| SCHEMBL11929013 | 0.79 | DPP7 (0.65) | DPP8DPP9DPP7NAMPTDPP4 | |
| SCHEMBL14048143 | 0.76 | DPP8 (0.54) | DPP8DPP9DPP7NAMPTTAS1R3 | |
| SCHEMBL10150901 | 0.76 | NOTUM (0.62) | DPP8DPP9DPP7NAMPTTAS1R3 | |
| SCHEMBL22271499 | 0.75 | DPP9 (0.56) | DPP8DPP9DPP7NAMPTTAS1R3 | |
| SCHEMBL20612060 | 0.74 | ROCK1 (0.48) | DPP8DPP9NAMPTHRH3DPP4 | |
| SCHEMBL16327224 | 0.74 | RAB9A (0.56) | TAS1R3TAS1R1TAS1R2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8221737-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | DPP8 693/4885DPP9 804/4885DPP7 560/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | DPP8 693/4885DPP9 804/4885DPP7 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.